LRRK2 and Parkinson disease: Our study identifies pSer106 RAB12 as an endogenous biomarker in easily accessible PBMCs from carriers of the most prevalent G2019S mutation, either PD-manifesting or non-manifesting, suggesting that pSer106 RAB12 can be used as a marker of LRRK2 activity in G2019S carriers.